drugset / Trial / NCT07128914
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study employs a single-arm, open-label, non-randomized, dose-escalation design to investigate the safety, tolerability, and efficacy of GO306 Recombinant Oncolytic Vaccinia Virus Injection. * Part 1: Utilizes the 3+3 design principle to evaluate the safety and tolerability of a single administration of GO306 at different dose levels. The primary goal is to determine the Maximum Tolerated Dose (MTD), providing the basis for selecting the Recommended Phase 2 Dose (RP2D). * Part 2: Evaluates the safety and tolerability of repeated intratumoral (IT) or intracavitary administrations of GO306 in patients with specific tumor types.
Timeline
- Start
- 2025-07-31
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GO306 | Unknown | 3e+07 unknown | Other |
| Subject | GO306 | Unknown | 3e+08 unknown | Other |
| Subject | GO306 | Unknown | 1e+09 unknown | Other |
Indications
No indication recorded.